Gold bars to be exempt from tariffs, White House clarifies
Investing.com - H.C. Wainwright raised its price target on ANI Pharmaceuticals (NASDAQ:ANIP) to $93.00 from $84.00 on Friday, while maintaining a Buy rating following the company’s strong second-quarter results. The stock, currently trading at $81.06, has shown impressive momentum with a 24.8% gain year-to-date and is trading near its 52-week high. According to InvestingPro data, two analysts have recently revised their earnings estimates upward for the upcoming period.
The pharmaceutical company reported adjusted earnings per share of $1.80 for the second quarter of 2025, exceeding FactSet consensus estimates of $1.41. The strong performance prompted ANI to raise its guidance for revenue, adjusted EBITDA, and EPS. InvestingPro analysis shows the company maintains healthy liquidity with a current ratio of 2.66, while demonstrating strong revenue growth of 30.3% over the last twelve months.
Cortrophin Gel sales were a key driver of ANI’s quarterly performance, reaching $81.6 million, representing 66% year-over-year growth from the second quarter of 2024 and a 54% sequential increase from the first quarter of 2025. Based on these results, ANI raised its full-year 2025 guidance for Cortrophin Gel to between $322 million and $329 million, up from the previous range of $265 million to $274 million.
The company reported that approximately 70% of new patient enrollments in July were written for the Cortrophin pre-filled syringe, indicating strong adoption of this delivery format. ANI also noted expectations for continued growth in the overall ACTH market.
H.C. Wainwright’s price target increase was attributed to upward earnings revisions following ANI’s commercial execution and enhanced cash flow generating capacity. While the company shows strong operational metrics, InvestingPro analysis indicates the stock is currently trading above its Fair Value. Subscribers can access 8 additional ProTips and a comprehensive Pro Research Report, part of our coverage of 1,400+ US stocks, to make more informed investment decisions.
In other recent news, ANI Pharmaceuticals reported impressive financial results for the second quarter of 2025, surpassing market expectations. The company achieved an adjusted non-GAAP earnings per share of $1.80, significantly higher than the projected $1.40. Additionally, ANI Pharmaceuticals reported revenue of $211.4 million, exceeding the forecasted $187.34 million. These results highlight a 28.57% surprise in earnings and demonstrate the company’s strong performance during this period. The positive earnings and revenue figures are crucial for investors evaluating the company’s financial health. Furthermore, the company’s stock experienced a notable increase in pre-market trading, reflecting investor confidence. These developments underscore ANI Pharmaceuticals’ ability to outperform market projections and deliver solid financial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.